Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


‘Standardized’ Comment From Brexit Minister Raises Hopes For Parallel EU/UK Drug Approval System

Executive Summary

The way in which pharmaceuticals might be regulated in the UK after the country leaves the EU is a big unknown. As MPs get to have their say on the matter, the Pink Sheet tries to gauge government thinking.


Related Content

UK Regulator Has Key Role in One in Four EU-Wide Approvals
Brexit Minister Says ‘No’ To UK Staying In EU Drug Regulatory Framework
Spanner In Works For UK Gvn’t’s Brexit Plans; Industry Looks To Ongoing Talks with Ministers
Spanner In Works For UK Gov’t’s Brexit Plans; Industry Looks To Ongoing Talks With Ministers
UK MPs On Brexit: EMA And MHRA Are ‘Completely Intermingled’
Brexit: UK Gov’t Says Retaining The EMA Cannot Be A “Line In The Sand” Matter
UK Pharma Chiefs To Helm Brexit Steering Committee





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts